BioCentury
ARTICLE | Financial News

Myriad sags following FY17 guidance

August 10, 2016 7:00 AM UTC

Molecular diagnostics company Myriad Genetics Inc. (NASDAQ:MYGN) fell $9.76 (33%) to $19.70 on Wednesday after the company provided FY17 revenue guidance that missed the consensus estimate.

Myriad expects FY17 revenues of $740-$760 million, including $168-$170 million in the current quarter, its fiscal 1Q17. The figures include expected revenues from pharmacogenomics testing company Assurex Health Inc. (Mason, Ohio), which Myriad is acquiring (see BioCentury Extra, Aug. 3). ...